Half Year 2026 CVS Group PLC Earnings Call-Q&A Transcript

Feb 26, 2026 / 09:30 AM GMT

Release Date Price: $16.22

Transcript

Key Points

Positve

CVS Group PLC (FRA:4C9) reported a 5.8% increase in revenue to £356.9 million, demonstrating growth despite weak consumer confidence in the UK.
Adjusted EBITDA rose by 3.9% to £67.7 million, with an EBITDA margin of 19%, indicating strong financial performance amidst inflationary pressures.
The company completed four veterinary practice acquisitions in Australia, expanding its presence to 33 practices across 55 sites.
CVS Group PLC (FRA:4C9) has successfully rebranded 60 of its sites, with plans to rebrand all UK companion animal practices by June, enhancing corporate identity and marketing capabilities.
The company maintains a low leverage ratio of 1.41 times, reflecting disciplined investment and strong cash conversion of 75%.

Negative

Price elasticity tests in Animed negatively impacted margins, as price reductions did not lead to increased revenue.
Inflationary pressures, including national insurance and minimum wage increases, reduced margins by approximately 1.5%.
The UK market for veterinary acquisitions remains challenging, with high multiples making it less attractive compared to opportunities in Australia.
Routine preventative care demand has softened due to economic concerns, affecting overall performance in some practices.
Compliance with CMA transparency measures, including rebranding and pricing transparency, is expected to cost approximately £6 million, impacting short-term financials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CVSG.L - CVS Group PLC
Half Year 2026 CVS Group PLC Earnings Call-Q&A
Feb 26, 2026 / 09:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Morning everyone, and welcome to this live stream of the CDES Group interim results following the release of those results early this morning.

I'm Richard Thamman, CEO of CBS. I'm joined by Robin Alfonso, our Chief Financial Officer, and Paul Higgs, our Chief Inveinary Officer.

We delivered further growth in both revenue and EBITDA in the period against a backdrop of weak consumer confidence in the UK.

Importantly, we've also taken a number of steps to position the group well for the future with our new CVS Vets joint branding live, our step up to the main market complete, and further successful growth in Australia.

Revenue in the period increased by 5.8% over the corresponding period in the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.